A Phase 1 interventional study of Tacrolimus in Chronic Graft Versus Host Disease Oral, sponsored by Children's Hospital Medical Center, Cincinnati. Completed at 1 site in United States. Open to participants aged 1 Year to 40 Years. Per ClinicalTrials.gov, last updated 2026-03-06.
Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States — 48 open to participants now, 70 under way, 7 of them phase 3. Bronchiolitis Obliterans Syndrome · United States.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, this one is the 235th largest by enrollment of the 260 interventional ones that give a count, is one of 20 that started in 2024, is one of 30 in phase 1, and was the 270th registered.
714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.
Browse Bronchiolitis Obliterans Syndrome studies →48 of the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States are open now. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Sarah Nikiforow, MD · Sites in United States
Ages 2+
Incyte Corporation · Sites in United States, Belgium, Germany and 3 more countries
Ages 2–17
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Australia, Brazil and 14 more countries
Ages 1–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.
This study: 1 Year to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
300 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 117 · Phase 3 33 · Phase 4 18
First in 2001; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 50 across 565 interventional studies indexed under Bronchiolitis Obliterans Syndrome.
Median enrollment 45 across the 260 interventional studies, 187 across the 39 observational. Of the 210 that completed or were terminated, 110 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
112 of 300 have an industry lead sponsor. The 10 most frequent:
Children's Hospital Medical Center, Cincinnati is the lead sponsor of 673 studies on the registry; 129 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 32 (56%) have results posted.
Children's Hospital Medical Center, Cincinnati has 4 studies filed under Bronchiolitis Obliterans Syndrome — fewer than ten, so there is no comparison to draw.
20 of the studies in Bronchiolitis Obliterans Syndrome with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01804686Phase 3Janssen Research & Development, LLCA Long-term Extension Study of PCI-32765 (Ibrutinib) | 2026-12-31 |
| NCT07395232Phase 3Dompé Farmaceutici S.p.AAn Efficacy and Safety Study of DFL24498 in the Treatment of AKC | 2027-03 |
| NCT02181257Phase 3Washington University School of MedicineExtracorporeal Photopheresis for Medicare Recipients of Lung Allografts | 2027-04 |
| NCT06585774Phase 3Incyte CorporationA Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease | 2027-09-28 |
| NCT06018766Steven Hays, MDLAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 300 studies in Bronchiolitis Obliterans Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the use of a novel formulation of tacrolimus, as a toothpaste, in a population of patients with oral chronic graft vs. host disease (cGVHD) as an adjunctive therapy in addition to standard-of-care systemic therapy.
The investigators plan to summarize our findings to add to the current body of literature regarding managing cGVHD, specifically those with oral involvement. Additionally, establishing effective topical application of tacrolimus in the oral cavity will allow for future prospective studies comparing outcomes for these patients with a more traditional standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Tacrolimus
Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
The presence of mucosal ulcerations
Utilizing the Mucosal Ulceration Index, the patient will be evaluated for the presence of mucosal ulcerations.
Time frame: Three months
Ran from Sep 2024 to primary completion in Sep 2025, 11 months.
Of 22 phase 1 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tacrolimus
Bronchiolitis Obliterans Syndrome →
Children's Hospital Medical Center, Cincinnati →